evipedia.ai
← Back

Horny Goat Weed for Health & Longevity

Evidence Review created on 09/21/2026 using AI4L / Opus 5

Also known as: Epimedium, Herba Epimedii, Epimedii Folium, Epimedium brevicornum, Epimedium sagittatum, Epimedium koreanum, Epimedium grandiflorum, Yin Yang Huo, Xian Ling Pi, Barrenwort, Bishop’s Hat, Fairy Wings, Rowdy Lamb Herb

Motivation

Horny goat weed (Epimedium) is a leafy plant that has been used in Chinese herbal practice for well over a thousand years and is now sold worldwide as a dietary supplement. Its best-known constituent, icariin, relaxes blood vessels through the same signaling route that prescription erection medicines act on, which is where the plant’s reputation as a libido aid comes from. The same plant compounds also behave like a weak plant estrogen inside bone.

Two very different bodies of work have grown up around this one plant. One comes from the sexual-performance supplement market, where horny goat weed is among the most frequently used ingredients and where independent testing of finished products has been a recurring concern. The other comes from bone research, where controlled human studies have been run in women after menopause. Reports of liver injury and of muscle and heart reactions sit alongside both.

This review examines what the human and laboratory evidence shows about horny goat weed for health and longevity: where its effects have been measured in people, where they have not, what harms have been documented, and how commercial preparations differ from one another.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of horny goat weed and its active compounds from expert and academic sources outside the systematic-review literature.

Content from four of the six priority platforms could not be included: Rhonda Patrick, Peter Attia, Chris Kresser and Lifespan.io have published nothing on horny goat weed, Epimedium or icariin, so no qualifying item exists from those sources.

Grokipedia

  • Horny goat weed

    A broad reference entry covering the plant, its icariin content, the phosphodiesterase-type-5 mechanism, and the gap between traditional claims and human data. Useful as an orientation before reading the primary literature.

Examine

  • Horny Goat Weed

    Grades the plant only for bone mineral density and notes that its human evidence base is one trial and one meta-analysis, while dose guidance for other uses is extrapolated from rodent studies.

ConsumerLab

Systematic Reviews

The systematic reviews and meta-analyses below cover the two areas where pooled human evidence exists — bone and the sexual-performance supplement market — together with a consolidated safety review. All are indexed on PubMed; note that the bone literature is produced almost entirely by Chinese traditional-medicine institutions, whose research programs are built around validating these herbs, and the Chinese Pharmacopoeia Commission that sets the Epimedium monograph is a state standards body rather than a membership organization earning revenue from the conclusions it endorses.

Mechanism of Action

Horny goat weed’s activity rests on a family of prenylated flavonoids, chiefly icariin, which gut bacteria strip to icariside II and then to icaritin before much of it is absorbed.

Three mechanisms dominate. First, icariin and icariside II inhibit phosphodiesterase type 5 (PDE5, the enzyme that destroys the messenger keeping blood-vessel muscle relaxed), so cyclic guanosine monophosphate (cGMP, that messenger) accumulates and vessels widen; potency at this target is orders of magnitude below that of prescription PDE5 inhibitors, and enzyme selectivity is correspondingly loose. Second, the same compounds act as weak phytoestrogens (plant molecules that fit the estrogen receptor), engaging estrogen receptor alpha (ERα, the main estrogen-sensing protein in bone) in bone-forming cells and raising the ratio of osteoprotegerin (OPG, a decoy protein) to RANKL (receptor activator of nuclear factor-κB ligand, the signal that matures bone-resorbing cells). Third, icariin suppresses NF-κB (nuclear factor-κB, an inflammatory master switch) and activates Nrf2 (nuclear factor erythroid 2-related factor 2, which turns on antioxidant genes).

A competing reading of the bone data holds the effect is not estrogenic but a downstream consequence of the same cGMP rise, since PDE5 inhibition by itself drives estrogen synthesis inside bone cells.

Pharmacologically, icariin is poorly water-soluble and is cleared mainly by intestinal bacterial deglycosylation and by UDP-glucuronosyltransferases (UGT enzymes, which attach sugars to speed excretion), with minor involvement of cytochrome P450 (the liver’s main drug-oxidizing enzyme family). Rodent oral bioavailability is roughly 12%, plasma half-life about 5–9 hours, and distribution favors liver, kidney, intestine and bone.

Historical Context & Evolution

Epimedium enters the written record as yin yang huo in the Shennong Bencao Jing, the Han-era Chinese materia medica, where it is classed as a kidney-yang tonic for impotence, cold limbs, and weak sinews and bones. The herdsman’s observation that gave the plant its English name — goats grazing it became conspicuously more active — is folkloric rather than documented, but the two traditional indications it was given, sexual function and skeletal weakness, are precisely the two that modern work has pursued.

Western interest arrived in two waves. In the 1990s the plant entered the supplement market purely as an aphrodisiac, on traditional-use claims. Then in the 2000s laboratory work identified icariin as a PDE5 inhibitor, supplying a plausible mechanism for the older claim; that finding was real and has been replicated, but its practical significance was overstated in marketing because the potency measured was far below that of the prescription drugs sharing the target, and oral absorption is poor.

The bone line developed separately in Hong Kong and Singapore academic groups and produced a 24-month placebo-controlled trial in 2007, still the plant’s strongest human dataset. Running against that, Chinese drug-safety monitoring from roughly 2016 onward attached liver-injury warnings to Epimedium-containing preparations. Neither line closes the file: the bone finding has not been replicated outside China, and the liver signal rests on spontaneous reports rather than controlled data, so both remain open.

Expected Benefits

High 🟩 🟩 🟩

Preservation of Bone Mineral Density After Menopause ⚠️ Conflicted

Epimedium prenylflavonoids engage estrogen receptors in bone-forming cells and shift the osteoprotegerin-to-RANKL ratio, slowing the accelerated loss that follows menopause. The evidence basis is one 24-month double-blind, placebo-controlled trial in 100 late-postmenopausal women plus meta-analyses pooling ten to twelve randomized trials. Nearly all pooled trials were Chinese, open-label, and used active comparators rather than placebo; a 2024 meta-analysis restricted to Epimedium total flavonoids found a lumbar-spine advantage that barely cleared significance and no femoral-neck difference. Read together, the lumbar-spine gain survives the disagreement while the femoral-neck effect does not.

Magnitude: In the 24-month placebo-controlled trial, lumbar-spine BMD rose 1.3% on Epimedium flavonoids while falling 2.4% on placebo (between-group p = 0.006), with femoral neck +1.6% versus −1.8% (p = 0.008) and urinary deoxypyridinoline, a marker of bone breakdown, down 39%; pooled across ten trials the lumbar effect was a standardized mean difference (SMD, an effect size in standard-deviation units) of 1.15, 95% confidence interval (CI, the range in which the true effect most likely lies) 0.61 to 1.70.

Medium 🟩 🟩

The pooled osteoporosis trials record faster resolution of the low back pain that accompanies vertebral bone loss, plausibly through the same shift in bone turnover rather than any direct pain-relieving action. The evidence is a meta-analysis of ten randomized trials in 890 patients, supported by a separate pooling of twelve trials reporting reduced pain scores. Those trials were open-label and single-country, so expectancy effects on a self-reported outcome cannot be excluded — which is why this sits below the density finding.

Magnitude: Pooled across ten randomized trials, time to relief of low back pain was about 11 days shorter with Epimedium than with comparator treatment (mean difference −11.38 days, 95% CI −12.63 to −10.12), and the overall clinical response was roughly four times likelier (odds ratio, the ratio of the odds of response between groups, 3.80, 95% CI 2.27 to 6.37).

Low 🟩

Breathlessness and Exercise Capacity in Chronic Obstructive Lung Disease

A placebo-controlled trial in 49 patients with stable chronic obstructive pulmonary disease (COPD, long-term airway narrowing causing breathlessness) found a Chinese yam and Epimedium mixture improved symptoms, quality of life and walking distance. The evidence is indirect: Epimedium was one of two herbs, and the trial is unreplicated.

Magnitude: Over three months the mixture improved total respiratory questionnaire score, a separately scored breathlessness rating and six-minute walking distance versus placebo (each p < 0.05); the report gives no effect size, confidence interval or between-group difference for any of these outcomes.

Depressive and Anxiety Symptoms

Icariin dampens neuroinflammatory signaling in rodent depression models, and an uncontrolled human pilot gave isolated icariin to ten patients with bipolar depression and active alcohol use for eight weeks, recording significant falls in clinician-rated depression and anxiety scores. Open-label, tiny, and testing the isolated flavonoid rather than the herb.

Magnitude: Over eight weeks the Hamilton depression score fell with an effect size of 0.8 (p = 0.012), the Hamilton anxiety score with an effect size of 1.4 (p = 0.005), and heavy drinking days with an effect size of 1.1 (p = 0.034) — all within-group changes in ten participants, with no control arm to compare against.

Speculative 🟨

Erectile Function and Libido

The plant’s signature claim. Icariin inhibits PDE5 and restores erectile responses in rodent models, but no controlled human trial of horny goat weed alone for erectile function or libido has been published.

Androgen Support

Rodent work reports raised testosterone at high doses, and the dose figures circulating in the supplement market are body-weight extrapolations from those rats. No human study has measured androgen levels on the herb.

Neuroprotection and Cognitive Aging

Icariin improves memory in rodent Alzheimer’s and diabetes models via reduced neuroinflammation. No human study has measured a cognitive outcome on the herb or its flavonoids; the published human work is pharmacokinetic.

Vascular and Metabolic Protection

Cell and animal work shows icariin limiting plaque formation, improving vessel-lining function and modifying blood lipids. Nothing is measured in people; the one registered human cardiovascular study posted no results.

Slowed Cellular Aging and Extended Lifespan

Icariin extends lifespan in nematodes and lowers senescence markers in cultured human kidney cells. No human study has measured an aging endpoint; the basis is invertebrate and cell work only.

Benefit-Modifying Factors

  • Menopausal status and baseline bone loss: The only positive human bone data come from women 10–18 years past menopause with lumbar T-scores (bone density versus a young-adult average) of −2.0 to −2.5. Benefit in men, younger women, or normal bone is unmeasured.

  • Baseline vitamin D and calcium: The 2007 trial gave every participant 300 mg elemental calcium daily. Bone-building signals cannot express themselves without substrate, so an uncorrected deficiency plausibly blunts any density effect.

  • Sex: All controlled bone evidence is in women, where the phytoestrogen mechanism is most relevant. The sexual-function claims are directed at men, and it is precisely there that human outcome data are absent.

  • Gut microbiome composition: Icariin must be deglycosylated by intestinal bacteria to icariside II and icaritin before meaningful absorption. Antibiotic exposure or a low-diversity microbiome plausibly reduces the delivered active dose.

  • Baseline testosterone and sexual function: Rodent benefits appear in animals with induced dysfunction, not healthy ones. Anyone starting with normal androgen levels and normal erectile function has the least theoretical room to gain.

  • Age at the older end of the target range: Adults past 70 have both the most bone to protect and the most concurrent medicines and the least liver reserve, which shifts the balance away from an agent with a liver signal.

  • Genetic polymorphisms in drug-metabolizing enzymes: Variants in UGT1A3 and UGT1A1 (genes for enzymes that attach sugars to flavonoids for excretion) alter icariin clearance in laboratory systems, and a slow-clearance variant would raise exposure from an identical dose.

  • Pre-existing estrogen-responsive conditions: Because the flavonoids act at estrogen receptors, women with endometriosis or fibroids may respond differently from those without, though the 24-month trial found no change in estradiol or endometrial thickness.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset and Allergic Skin Reactions

Nausea, dry mouth and loose stools, along with mild itching or rash, are the adverse events actually recorded when Epimedium is given under trial conditions. The basis is systematic pooling of ten randomized trials in 890 osteoporosis patients and a second pooling of six trials in 838, both describing the events as mild and self-limiting. Severity is low and reversal on stopping is the rule. One case report describes a vasculitic rash (inflamed skin blood vessels) after co-ingestion with Ginkgo biloba, where attribution between the herbs was unresolved.

Magnitude: Pooled total complication rates did not differ from comparator treatment: relative risk (RR, the ratio of event rates between groups) 0.68, 95% CI 0.39 to 1.19, p = 0.18, across 838 patients in six trials; the larger ten-trial pooling describes adverse reactions as infrequent and confined to mild gastrointestinal upset or skin allergy.

Medium 🟥 🟥

Undeclared Prescription Erectile-Dysfunction Drugs in Commercial Products

This is a risk of the product category rather than of the plant. Horny goat weed is one of the most common ingredients in online sexual-performance supplements, a market in which an assessment of the US regulator’s tainted-supplements database and repeated regulatory recalls have found undeclared sildenafil and sildenafil analogues. The clinical consequence is a genuine PDE5 inhibitor dose taken unknowingly, which can produce severe hypotension (dangerously low blood pressure) in anyone on nitrates or alpha-blockers. Evidence is consistent laboratory testing and post-marketing safety reporting rather than trial data.

Magnitude: Independent testing of sexual-enhancement supplements has repeatedly failed most products — 13 of 22 failed in one round of ConsumerLab testing and 7 of 10 in another — and a 2025 recall of a horny goat weed capsule product followed detection of both sildenafil and propoxyphenyl-sildenafil, an unapproved analogue, in a single lot.

Low 🟥

Drug-Induced Liver Injury

Epimedium carries a liver-injury signal concentrated in the multi-herb preparation Xianling Gubao, for which susceptibility factors and biomarkers have been profiled from clinical cases and which prompted regulatory warnings. Injury appears idiosyncratic rather than dose-dependent and usually resolves on withdrawal.

Magnitude: Not quantified in available studies. The randomized trial that did monitor liver chemistry ran six weeks in 58 women and found no change, far too small and too brief to catch an idiosyncratic event, so no incidence can be derived; the human record consists of spontaneous adverse-event reports and hospital case series in which the herb was one component of a multi-herb preparation.

Rapid Heart Rate and Mood Elevation

A published case report describes tachyarrhythmia (an abnormally fast heart rhythm) with hypomania (elevated mood, reduced need for sleep, racing thoughts) in a patient taking horny goat weed, resolving after withdrawal. The vessel-widening effect offers a mechanism. Uncontrolled single-patient data; no trial has looked systematically.

Magnitude: Not quantified in available studies. The outcome rests on one case report, so no rate, effect size or exposure threshold exists; the randomized osteoporosis trials did not monitor cardiac rhythm or mood as endpoints.

Severe Muscle Cramping with Raised Creatine Kinase

A 2025 case report describes a man admitted with ten hours of severe muscle spasms, raised creatine kinase (CK, an enzyme released when muscle is damaged) and raised creatinine after one month of an Epimedium supplement, all resolving on withdrawal. Uncontrolled single-patient data; no mechanism is established.

Magnitude: Not quantified in available studies. This is a single first-of-kind case report, so neither incidence nor a dose-response relationship can be derived; the randomized trial that checked renal chemistry found no change, and no trial has tracked creatine kinase.

Speculative 🟨

Stimulation of Hormone-Sensitive Tissue

The flavonoids bind estrogen receptors including ERα36, raising a theoretical concern in breast, endometrial or other hormone-driven disease. No human outcome data exist; the 24-month trial found no endometrial thickening.

Breathing Difficulty at High Intake

Drug-reference monographs list severe breathing problems among the reactions reported at large intakes of the herb. The basis is monograph summaries of unverified reports rather than controlled data, with no mechanism confirmed in people.

Increased Bleeding Risk from Platelet Inhibition

Epimedium extracts and icariin suppress platelet aggregation and thrombus formation in laboratory and rodent work, and drug-reference monographs carry a bleeding caution. No human bleeding outcome has been measured.

Low Blood Pressure and Fainting

Drug-reference monographs list dizziness, low blood pressure and fainting among reported reactions, which the vessel-widening action would explain. The basis is unverified report summaries, not controlled data, so no incidence exists.

Risk-Modifying Factors

  • Pre-existing liver disease: Reduced hepatic reserve is the single factor most likely to convert an idiosyncratic Epimedium liver reaction into a clinically significant one; active hepatitis or cirrhosis removes the margin that allows spontaneous recovery.

  • Species and preparation used: Epimedium koreanum shows markedly greater hepatotoxicity than E. brevicornum or E. sagittatum in comparative animal work, and ethanol extracts concentrate the implicated constituents more than decoctions.

  • Concurrent hepatotoxic or CYP1A2-handled drugs: Epimedium-containing preparations induce CYP1A2 (a liver enzyme that converts some drugs to reactive metabolites), which amplified flutamide liver injury in mice — a plausible route to additive harm.

  • Sex and hormonal status: The estrogen-receptor activity makes women with hormone-sensitive conditions the group in which the theoretical endocrine risk concentrates, while the cardiac and muscle case reports both occurred in men.

  • Baseline liver enzymes and creatine kinase: Someone starting with alanine aminotransferase already above the functional range, or with chronically raised creatine kinase, has no headroom to distinguish a new adverse signal from their own baseline.

  • Age and concurrent medicines: Older adults combine reduced hepatic clearance with more medicines taken at the same time, so both the liver signal and the vasodilatory interaction risk rise with age across the target range.

  • UGT and glucuronidation variants: Polymorphisms in UGT1A3 and UGT1A1, genes for the enzymes that conjugate icariin for excretion, alter clearance in laboratory systems and would raise exposure in slow conjugators.

  • Cardiovascular disease and antihypertensive use: Existing low blood pressure, unstable blood-pressure control or arrhythmia makes the reported tachyarrhythmia and the vasodilatory effect more consequential than they would be in a healthy vascular system.

Key Interactions & Contraindications

  • Nitrates (nitroglycerin, isosorbide mononitrate, amyl nitrite): Absolute contraindication where products may be adulterated with sildenafil analogues. Consequence is profound, potentially fatal hypotension. Mitigation: never combine, and avoid sexual-performance blends entirely if on nitrates.

  • PDE5 inhibitors (sildenafil, tadalafil, vardenafil): Caution. Additive vasodilation with headache, flushing and hypotension. Mitigation: separate use rather than stacking, and treat any “natural” product taken alongside as a possible second dose of the same drug.

  • Antihypertensives and alpha-blockers (amlodipine, lisinopril, tamsulosin, doxazosin): Caution. Additive blood-pressure lowering with dizziness or fainting on standing. Mitigation: monitor seated and standing blood pressure for the first two weeks.

  • Anticoagulants and antiplatelets (warfarin, apixaban, aspirin, clopidogrel): Caution. Epimedium flavonoids inhibit platelet activation in laboratory work, giving an additive bleeding-risk signal. Mitigation: stop 7–14 days before elective surgery.

  • Hepatotoxic and CYP1A2-handled drugs (flutamide, isoniazid, methotrexate, acetaminophen at high intake): Caution. Epimedium preparations induce CYP1A2 and amplified flutamide liver injury in mice. Mitigation: liver enzymes checked at 4–8 weeks if combined.

  • Statins and other OATP1B1 substrates (simvastatin, atorvastatin, rosuvastatin): Monitor. Icariin inhibits organic anion transporting polypeptide 1B1 (OATP1B1, a liver uptake transporter) in laboratory work, which would raise statin exposure and the risk of myopathy (muscle pain and damage).

  • Estrogen-modulating therapy (tamoxifen, raloxifene, anastrozole, letrozole, estradiol): Caution. Phytoestrogen activity may oppose or add to intended receptor blockade. Mitigation: avoid during active endocrine therapy for hormone-sensitive cancer.

  • Buprenorphine and opioid-agonist therapy: Caution. A published case report attributes surging opioid cravings in a patient stabilized on buprenorphine to Epimedium interference with CYP3A4 (a liver enzyme that clears buprenorphine). Mitigation: avoidance during opioid-use-disorder treatment.

  • Over-the-counter sympathomimetics and stimulants (pseudoephedrine, phenylephrine, high-dose caffeine, yohimbine): Caution. Sympathomimetics mimic adrenaline, so cardiac stimulation is additive given the reported tachyarrhythmia. Mitigation: separate intake and avoid combined sexual-performance blends, which routinely stack yohimbine.

  • Over-the-counter analgesics (ibuprofen, naproxen, acetaminophen): Monitor. Regular non-steroidal use adds gastrointestinal irritation to the commonest Epimedium adverse event; acetaminophen adds a second hepatic load.

  • Supplements with additive vasodilatory effect (L-Arginine, L-Citrulline, beetroot nitrate, Panax ginseng, Pycnogenol pine bark extract): Caution. Additive blood-pressure lowering. Mitigation: introduce one at a time and re-check blood pressure.

  • Supplements with additive bleeding or hepatic risk (Ginkgo biloba, fish oil above 3 g daily, high-dose vitamin E, green tea extract, kava): Caution. Additive bleeding or liver load; the vasculitic-rash case involved Ginkgo biloba. Mitigation: introduce singly and observe the 7–14 day presurgical washout.

  • Phytoestrogenic supplements (soy isoflavones, red clover, black cohosh, Pueraria mirifica): Monitor. Additive estrogen-receptor activity of uncertain net direction, risking stimulation of breast or endometrial tissue in hormone-sensitive disease. Mitigation: avoid stacking phytoestrogens.

  • Other interventions — hormone replacement therapy and bisphosphonates (bone-breakdown blockers such as alendronate, risedronate and zoledronic acid): Monitor. Epimedium has been trialed alongside standard osteoporosis drugs without evident excess harm, but an unquantified estrogenic load on top of systemic hormone therapy risks endometrial stimulation.

Populations who should avoid Horny Goat Weed:

  • Pregnancy and breastfeeding at any stage — no human safety data exist, and the compounds are estrogenically active.
  • Hormone-sensitive cancers (breast, endometrial, ovarian, prostate) whether active or in remission.
  • Active liver disease, or any chronic liver condition with a Child-Pugh score of B or C.
  • Anyone on nitrate therapy, including recent myocardial infarction within 90 days where nitrates are standard.
  • Known arrhythmia, including atrial fibrillation and documented supraventricular tachycardia.
  • Bipolar spectrum disorder, given the reported hypomania.
  • Patients on buprenorphine or methadone maintenance for opioid use disorder.
  • Chronic kidney disease at stage 4 or worse (estimated glomerular filtration rate below 30 mL/min/1.73 m²).
  • Within 14 days of elective surgery, given the platelet signal.
  • Children and adolescents under 18.

Risk Mitigation Strategies

  • Baseline and follow-up liver panel: Aminotransferases and bilirubin measured before starting, at 6–8 weeks, then every 6 months catch the idiosyncratic liver injury while it is still silent and reversible.

  • Deliberate species selection: Products declaring Epimedium brevicornum or E. sagittatum rather than E. koreanum, which carries the strongest experimental hepatotoxicity signal, reduce the most serious documented risk.

  • Single-ingredient products over performance blends: A plain extract with a declared icariin percentage sidesteps the adulteration risk — undeclared sildenafil analogues appear overwhelmingly in stacked performance formulas, not in plain extracts.

  • Low starting dose with slow titration: Roughly 500 mg of a 10% standardized extract, about 50 mg icariin daily, held two weeks before any increase limits gastrointestinal upset and reveals idiosyncratic reactions early.

  • Blood pressure check in the first fortnight: Seated and standing readings taken twice weekly for two weeks, particularly alongside antihypertensives, catch additive hypotension before it produces a fall.

  • Washout 7–14 days before surgery or dental extraction: The platelet-inhibition signal is laboratory-grade but additive with anticoagulants, and a defined washout removes any contribution to perioperative bleeding.

  • Immediate discontinuation on warning symptoms: Dark urine, right-upper-abdominal pain, jaundice, palpitations, unexplained muscle cramping or a spreading rash all warrant stopping and testing rather than dose reduction.

  • Ceiling below marketed extrapolations: The 900–1,500 mg icariin figures circulating online are rat-study body-weight conversions, not human doses; staying below them avoids untested exposures that raise the liver and cardiac risks documented here.

Therapeutic Protocol

  • Bone protocol dose: 60 mg icariin daily as a standardized Epimedium flavonoid preparation, with 300 mg elemental calcium — the regimen used in the Chinese University of Hong Kong 24-month trial led by Qin and Zhang.

  • Supplement-market dose: 500–1,000 mg of extract standardized to 10–20% icariin, delivering roughly 50–200 mg icariin daily. This range is conventional among vendors rather than trial-derived.

  • Traditional decoction: 6–10 g of dried aerial parts simmered as a decoction, the range specified in the Chinese Pharmacopoeia monograph and still the form used in clinical traditional practice.

  • Competing approaches: The bone approach uses a standardized purified flavonoid fraction at a fixed low dose for years; the sexual-performance approach uses high-percentage extracts episodically. Neither has been tested against the other.

  • Half-life and dose splitting: In human dosing icariin is undetectable in serum; its metabolites peak at about 4 hours (icariside II) and 24 hours (desmethylicaritin), so the single daily dose the bone trial used is defensible.

  • Best time of day: Morning and early afternoon with meals. Taking a vasodilatory, possibly stimulating compound late suits nobody reporting palpitations, and food containing fat aids absorption of a poorly soluble flavonoid.

  • Genetic considerations: Slow-conjugating UGT1A1 and UGT1A3 variants raise icariin exposure from a given dose in laboratory systems, arguing for the lower end of any range where such a variant is known.

  • Sex-based differences: Every positive human dose figure comes from postmenopausal women. No dose has been validated in men, so the male supplement doses in circulation are extrapolations, not findings.

  • Age considerations: Beyond 70, reduced hepatic clearance and more concurrent medicines argue for the 60 mg icariin trial dose rather than the higher market doses, with liver monitoring brought forward.

  • Baseline biomarkers guiding dose: Vitamin D and calcium repletion precedes bone use, since the trial protocol supplied calcium daily and the flavonoid effect operates on bone turnover rather than on substrate supply.

  • Pre-existing conditions: Any liver, cardiac-rhythm or hormone-sensitive condition moves the decision from dose selection to whether to use the herb at all, as set out under Contraindications.

Discontinuation & Cycling

  • Lifelong versus short-term: The only positive human protocol ran continuously for 24 months, so bone use is inherently long-term; episodic use for sexual performance has no trial basis at all.

  • Withdrawal effects: None documented. No published report describes a withdrawal syndrome, rebound phenomenon or dependence on Epimedium or its flavonoids in humans or animals.

  • Tapering: Not required. Every case report of an adverse reaction describes abrupt cessation with resolution, and no pharmacology suggests a taper is needed.

  • Cycling: Not established for efficacy. Cycling 8–12 weeks on and 2–4 weeks off is common practice in the supplement market, but no study has compared continuous with intermittent use.

  • Practical case for scheduled breaks: A planned break every 3 months provides an off-drug window in which liver enzymes and symptoms can be reassessed without the herb confounding them, which is a safety rather than efficacy rationale.

  • Stopping for a defined reason: If the bone markers or density scan show no movement at 12 months on an adequate dose, the trial evidence gives no basis for continuing beyond that point.

Sourcing and Quality

  • Species declaration: The botanical name on the label is the first discriminator. Epimedium brevicornum and E. sagittatum dominate the positive literature; E. koreanum carries the strongest liver signal, and an unnamed “Epimedium extract” could be any of about 52 species.

  • Icariin standardization: A declared icariin percentage verified by high-performance liquid chromatography (HPLC, a laboratory method that separates and quantifies individual plant compounds) is what makes dose knowable; wild-harvested material varies several-fold in flavonoid content.

  • Third-party testing: Products carrying NSF International, United States Pharmacopeia or Informed Choice certification have been screened for undeclared pharmaceuticals, the specific failure mode that has repeatedly hit this ingredient category.

  • Heavy metals and adulterant screening: A batch certificate of analysis covering lead, cadmium, arsenic and mercury plus a sildenafil-analogue screen is the relevant document; Epimedium is a root-and-leaf crop from regions with documented soil contamination.

  • Reputable suppliers: Nootropics Depot, Thorne and Pure Encapsulations publish batch certificates; Life Extension sells a standardized extract. Compounding pharmacies are not relevant, as the herb is not a prescription preparation.

  • Formulation and form: Powdered whole herb, ethanol extract and purified flavonoid fraction are not interchangeable. The bone trial used a purified fraction; ethanol extracts concentrate the constituents most implicated in liver injury.

  • Avoid proprietary blends: Any label listing “proprietary blend” without per-ingredient milligrams makes dose and adulteration risk unassessable, and these formulas are where undeclared prescription drugs have overwhelmingly been found.

Practical Considerations

  • Time to effect: Bone density changes were measurable at 12 months and clearest at 24 in the only controlled trial. Nothing supports an acute sexual-performance effect within hours, which is what most purchasers expect.

  • Common pitfall — expecting a prescription-strength effect: Icariin’s potency at PDE5 is orders of magnitude below sildenafil’s, and oral absorption is poor. Dose escalation to close that gap raises liver and cardiac risk without evidence of benefit.

  • Common pitfall — buying the category rather than the compound: Multi-ingredient “male enhancement” formulas carry the adulteration risk while obscuring the actual icariin dose. A plain standardized extract avoids both problems.

  • Common pitfall — rodent dose conversion: The 900–1,500 mg icariin figures widely republished online are body-weight conversions from rat testosterone studies. No human has been studied at anything approaching them.

  • Regulatory status: In the United States it is a dietary supplement under the 1994 supplement law, meaning no pre-market efficacy or safety review and no Food and Drug Administration (FDA, the US regulator of foods, drugs and supplements) approval for any use.

  • Regulatory divergence: China lists Epimedium as a pharmacopoeial herb with liver-injury labeling on containing preparations, so the same material is a warned medicine in one jurisdiction and an unreviewed supplement in another.

  • Cost and structural incentives: Standardized extracts run roughly 20–40 US dollars monthly, against a few dollars for generic alendronate or sildenafil. Payers therefore have no incentive to fund research on a costlier unpatentable alternative, which plausibly shapes what gets studied.

  • Accessibility: Widely available without prescription in the United States and most of Europe; the purified flavonoid fraction used in the bone trial is not sold as a consumer product anywhere.

Interaction with Foundational Habits

  • Sleep: Potentially disruptive, direction negative. The vasodilatory and reported stimulating effects, plus the single case of hypomania with reduced sleep need, argue for morning and early-afternoon dosing. No trial has measured sleep architecture on Epimedium, so the concern is mechanistic and anecdotal rather than demonstrated.

  • Nutrition: Direct and potentiating. Icariin is poorly water-soluble, so absorption improves with a fat-containing meal. Intestinal bacteria must deglycosylate it before meaningful uptake, making fermentable fiber intake plausibly relevant, while recent broad-spectrum antibiotics plausibly reduce the delivered active dose.

  • Exercise: Indirect, no blunting known. Nothing suggests interference with hypertrophy (muscle growth) or endurance adaptation. The practical point runs the other way: hard resistance training raises creatine kinase for up to 72 hours, which can mask or mimic the muscle-injury signal described in the 2025 case report.

  • Stress management: Indirect and speculative. Icariin dampens stress-hormone signaling and inflammatory activation in rodent models, and the patient in the muscle-spasm case report took it explicitly for mood and anxiety. No human study has measured cortisol or a validated stress measure on the herb.

Monitoring Protocol & Defining Success

Before starting, a liver and muscle baseline — aminotransferases, bilirubin, creatine kinase, creatinine — is the essential set, because the documented harms are hepatic and muscular and cannot be interpreted later without a starting value. For a bone indication, vitamin D, calcium, bone turnover markers and a density scan are added, since these define both whether the substrate is adequate and what success would look like. Resting blood pressure and, in men, two morning testosterone values complete the baseline.

Ongoing, liver enzymes and creatine kinase are rechecked at 6–8 weeks, then at 6 months, then every 6–12 months while use continues. Blood pressure warrants twice-weekly self-measurement for the first fortnight only. Bone turnover markers are informative at 3–6 months; a density scan is uninformative before 12–24 months, because shorter intervals fall inside the measurement error of the scan itself.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine and aspartate aminotransferase 10–26 U/L (women); 10–30 U/L (men) Detects the idiosyncratic liver injury reported with Epimedium preparations U/L = units per liter. Conventional labs call up to 40–55 U/L normal, well above this functional target. Draw fasting; confirm any rise on a repeat before acting
Total bilirubin 0.3–1.0 mg/dL Separates a harmless enzyme rise from genuine liver dysfunction Also raised by Gilbert syndrome, a common benign inherited variant of bilirubin processing. Best paired with the aminotransferases in the same draw
Creatine kinase 40–200 U/L Picks up the muscle injury described in the 2025 case report Avoid drawing within 72 hours of hard resistance training, which raises it independently. Pair with creatinine, since both rose together in that report
Creatinine and estimated glomerular filtration rate Creatinine 0.6–1.0 mg/dL (women), 0.8–1.2 mg/dL (men); eGFR above 90 mL/min/1.73 m² Muscle breakdown and kidney strain track together eGFR = estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Fasting not required; add cystatin C where muscle mass is unusually high or low
25-hydroxyvitamin D 40–60 ng/mL Any bone effect depends on adequate vitamin D and calcium substrate The conventional sufficiency cut-off of 30 ng/mL sits below this functional target. Draw any time of day; retest 8–12 weeks after changing intake
C-terminal telopeptide and procollagen type 1 N-terminal propeptide CTX in the lower half of the premenopausal reference range; P1NP mid-range Shows within 3–6 months whether bone breakdown is actually slowing CTX = C-terminal telopeptide, a marker of bone breakdown; P1NP = procollagen type 1 N-terminal propeptide, a marker of bone building. Both need a morning fasted draw, as they fall through the day
Bone mineral density by bone scan T-score above −1.0, and change from the individual’s own baseline This is the outcome the one controlled human trial actually measured DXA = dual-energy X-ray absorptiometry, the standard bone scan. Repeat no sooner than 12–24 months; shorter intervals fall inside the scan’s measurement error
Resting blood pressure 110–125 / 70–80 mmHg The vessel-relaxing action can add to blood-pressure-lowering treatment mmHg = millimeters of mercury. Measure seated after 5 minutes of rest, average two readings, and add a standing reading if dizziness occurs
Total and free testosterone (men) Total 500–800 ng/dL; free 15–25 ng/dL Tests the unproven androgen claim against the individual’s own starting point Draw fasting before 10 a.m. Confirm on a second morning before acting; single values vary widely. Conventional ranges extend down to 300 ng/dL total
Estradiol (women) No established target for this use; track change from the individual’s own baseline The flavonoids act at estrogen receptors, so a shift would be the signal of concern Ask for liquid chromatography–mass spectrometry, which is accurate at low postmenopausal levels where immunoassays are not. The 24-month trial found no change in estradiol or endometrial thickness

Qualitative markers worth tracking alongside the laboratory values:

  • Spontaneous erection frequency and morning erections, recorded weekly rather than recalled
  • Libido and sexual satisfaction, scored simply and consistently
  • Energy through the day, and whether it arrives as steadiness or as jitteriness
  • Sleep onset latency and night-time awakenings, especially in the first fortnight
  • Mood stability, with explicit attention to unusual elation, irritability or reduced need for sleep
  • Muscle cramping, unusual soreness or dark urine, any of which warrants stopping and testing
  • Back pain and standing tolerance where the indication is bone
  • Appetite, nausea and stool consistency, the commonest adverse events in trial conditions

Emerging Research

  • Phase 3 trial of the purified derivative icaritin in liver cancer: NCT05594927 randomizes 261 patients with unresectable hepatocellular carcinoma to icaritin soft capsules versus an active comparator, with biomarker enrichment. Sponsored by Beijing Shenogen Biomedical, which manufactures the drug — a direct commercial interest in the result.

  • Terminated phase 3 trial against sorafenib: NCT03236649 compared icaritin with sorafenib in 89 patients with advanced liver cancer and was terminated. Termination of the same sponsor’s head-to-head comparison against standard therapy is the clearest negative signal in this program.

  • Phase 1 study of Epimedium prenylflavonoid extract: NCT02931305 enrolled 30 participants to examine a standardized extract for osteoporosis and cardiovascular disease. This is the registered study closest to the herb rather than a purified derivative; its single-dose pharmacokinetic results are published.

  • Icaritin in pancreatic cancer: NCT06825546 is recruiting 70 patients with previously untreated advanced pancreatic cancer for icaritin combined with chemotherapy, testing whether the derivative’s activity extends beyond liver cancer.

  • Completed negative botanical trial: NCT02909686 tested Epimedium sagittatum against placebo in 36 men with Gulf War Illness. Neither dose reduced symptom severity — a controlled human result running against the plant’s energy and vitality claims.

  • Bioavailability as the rate-limiting question: Szabó et al., 2022 review the formulation strategies being developed to overcome icariin’s poor solubility. If absorption improves substantially, every existing dose and safety figure would need revisiting.

  • Hepatotoxicity mechanism and susceptibility markers: Li et al., 2020 profile clinical susceptibility factors and candidate biomarkers for Epimedium-preparation liver injury. Identifying who is at risk could either narrow the warning to a small subgroup or widen it.

  • Preclinical neurology pipeline: Cui et al., 2026 pool animal Alzheimer’s studies of icariin. The methodological quality assessment in such syntheses is what determines whether a human trial is justified, and it is the gating step here.

Conclusion

Horny goat weed is a Chinese medicinal plant whose plant compounds relax blood vessels through the same enzyme target as prescription erection medicines and act weakly like estrogen inside bone. Those two mechanisms explain both its traditional reputation and its modern following, but the human evidence behind them is very unevenly distributed. Bone is where it is strongest: a two-year blinded, placebo-controlled study in women well past menopause, supported by pooled trial data, shows preserved bone density and reduced back pain. Sexual function, the reason most people buy it, has no controlled human study of the plant at all — the case there rests on animal work and on a laboratory potency far below the drugs it is compared with.

The evidence base is limited in other ways too. Almost all bone trials come from one country and from institutions built around validating traditional herbs; the largest trials of a purified plant derivative were run by the company that manufactures it; and the marketing claims come from the sellers. Harms are real but poorly counted: liver injury, disturbed heart rhythm and muscle damage each rest on scattered reports rather than systematic measurement, and commercial products have repeatedly been found to contain undeclared prescription drugs. For someone weighing this plant, the gap between what has been measured and what is claimed is the central fact.

Top - Benefits - Risks - Protocol